FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
暂无分享,去创建一个
F. Nevens | J. Trebicka | O. Govaere | W. Laleman | R. Farré | M. Mazzone | R. Schierwagen | I. Mannaerts | L. V. van Grunsven | S. Klein | Ingrid Vander Elst | Petra Windmolders | M. Wenes | L. Verbeke
[1] R. del Campo,et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. , 2016, Journal of hepatology.
[2] F. Tacke,et al. In search of the magic bullet: can liver inflammation and fibrosis be reversed with medications? , 2015, Expert review of gastroenterology & hepatology.
[3] K. Lindor,et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.
[4] B. Neuschwander‐Tetri,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.
[5] T. Roskams,et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. , 2015, The American journal of pathology.
[6] T. Roskams,et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats , 2014, Hepatology.
[7] Frank Tacke,et al. Macrophage heterogeneity in liver injury and fibrosis. , 2014, Journal of hepatology.
[8] F. Schuit,et al. Gene Expression Profiling of Early Hepatic Stellate Cell Activation Reveals a Role for Igfbp3 in Cell Migration , 2013, PloS one.
[9] R. Schwabe,et al. Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.
[10] R. Schwabe,et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice , 2013, Hepatology.
[11] T. Luedde,et al. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects , 2013, Fibrogenesis & tissue repair.
[12] T. Luedde,et al. Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver Fibrosis , 2013, The Journal of Immunology.
[13] M. Odenthal,et al. Class II HDAC Inhibition Hampers Hepatic Stellate Cell Activation by Induction of MicroRNA-29 , 2013, PloS one.
[14] S. Malik,et al. Quercetin suppresses inflammation by reducing ERK1/2 phosphorylation and NF kappa B activation in Leptin-induced Human Umbilical Vein Endothelial Cells (HUVECs) , 2013, BMC Research Notes.
[15] T. Sauerbruch,et al. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. , 2012, Journal of hepatology.
[16] S. Coulon,et al. Leptin-mediated reactive oxygen species production does not significantly affect primary mouse hepatocyte functions in vitro , 2012, European journal of gastroenterology & hepatology.
[17] F. Lammert,et al. Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats , 2012, Laboratory Investigation.
[18] L. Adorini,et al. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. , 2012, Drug discovery today.
[19] F. Nevens,et al. Bench-to-beside review: Acute-on-chronic liver failure - linking the gut, liver and systemic circulation , 2011, Critical care.
[20] Peter D Siersema,et al. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-κB signaling in the intestine. , 2011, Biochimica et biophysica acta.
[21] G. Guo,et al. Tissue-specific function of farnesoid X receptor in liver and intestine. , 2011, Pharmacological research.
[22] P. Siersema,et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease , 2011, Gut.
[23] F. Lammert,et al. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. , 2010, Journal of hepatology.
[24] Scott L. Friedman,et al. Evolving challenges in hepatic fibrosis , 2010, Nature Reviews Gastroenterology &Hepatology.
[25] Jun-ji Ma,et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. , 2010, Journal of hepatology.
[26] V. Rogiers,et al. Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo , 2010, Hepatology.
[27] K. Zatloukal,et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. , 2009, The American journal of pathology.
[28] E. Distrutti,et al. The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis1 , 2009, The Journal of Immunology.
[29] R. Schwabe,et al. CCR2 promotes hepatic fibrosis in mice , 2009, Hepatology.
[30] B. M. Forman,et al. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.
[31] S. Friedman,et al. Mechanisms of hepatic fibrogenesis. , 2008, Gastroenterology.
[32] R. Hay,et al. NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. , 2008, Journal of hepatology.
[33] S. Dooley,et al. Profibrogenic transforming growth factor‐β/activin receptor–like kinase 5 signaling via connective tissue growth factor expression in hepatocytes , 2007, Hepatology.
[34] A. Elsharkawy,et al. Nuclear factor‐κB and the hepatic inflammation‐fibrosis‐cancer axis , 2007 .
[35] Didier Merlin,et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. , 2007, Cancer research.
[36] F. Nevens,et al. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. , 2007, Gastroenterology.
[37] Y. Inagaki,et al. Emerging insights into Transforming growth factor β Smad signal in hepatic fibrogenesis , 2007, Gut.
[38] Yun Yen,et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. , 2007, Cancer research.
[39] He-sheng Luo,et al. Reversal Effect of Thalidomide on Established Hepatic Cirrhosis in Rats via Inhibition of Nuclear Factor-κB/Inhibitor of Nuclear Factor-κB Pathway , 2007 .
[40] A. Elsharkawy,et al. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. , 2007, Hepatology.
[41] He-sheng Luo,et al. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. , 2007, Archives of medical research.
[42] T. Roskams,et al. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited , 2006, European journal of clinical investigation.
[43] F. Nevens,et al. Portal hypertension: from pathophysiology to clinical practice , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[44] C. J. Marek,et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. , 2005, Gastroenterology.
[45] S. Friedman,et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis , 2004, Gut.
[46] A. Morelli,et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. , 2004, Gastroenterology.
[47] T. Willson,et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.
[48] J. Iredale,et al. Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Timp-1 is Mediated via Effects on Mmp Inhibition: Implications for Reversibility of Liver Fibrosis , 2002 .
[49] John P. Iredale,et al. Inhibition of Apoptosis of Activated Hepatic Stellate Cells by Tissue Inhibitor of Metalloproteinase-1 Is Mediated via Effects on Matrix Metalloproteinase Inhibition , 2002, The Journal of Biological Chemistry.
[50] T. Roskams,et al. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. , 2001, Journal of hepatology.
[51] P. Bioulac-Sage,et al. [Mechanisms of hepatic fibrogenesis]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[52] N. Fausto,et al. Tumor Necrosis Factor Induces DNA Replication in Hepatic Cells through Nuclear Factor {{kappa}}B Activation , 1999 .
[53] N. Fausto,et al. Tumor necrosis factor induces DNA replication in hepatic cells through nuclear factor kappaB activation. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[54] S. Harrison,et al. Structure of an IκBα/NF-κB Complex , 1998, Cell.
[55] S. Harrison,et al. Structure of an IkappaBalpha/NF-kappaB complex. , 1998, Cell.
[56] J. Iredale,et al. Pathogenesis of liver fibrosis. , 1997, Clinical science.
[57] H. Herbst,et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. , 1996, The American journal of pathology.